Baidu
map

姬军生:后医改时代传染病医院建设发展重点

2018-01-02 姬军生 科学网

自今年4月北京市启动医药分开综合改革以来,取消药品加成收取医事服务费,降低CT、MR检查费用,提高护理费、床位费,调整了435种医疗服务项目价格,目前已经取得了显著效果。

自今年4月北京市启动医药分开综合改革以来,取消药品加成收取医事服务费,降低CT、MR检查费用,提高护理费、床位费,调整了435种医疗服务项目价格,目前已经取得了显着效果。

医改政策将按照国家的发展战略持续推进,薪酬制度的改革、现代医院管理制度建立、DRG-s的实施、分级诊疗等针对公立医院改革的若干措施会逐步推开。传染病医院作为国家医药卫生健康事业中一支特殊力量,必须调整传统思路,积极推进各项改革。

服务手段与技术特色双管齐下

医改后,一些业务合理分流给基层医院,传染病专科医院必须在服务手段上改进,在技术特色上提升,才能保持自身的生存和竞争能力。

在服务方面,大力发展互联网医疗,用信息化手段改造门诊服务,可提升病人就诊体验,增加服务的便捷性、及时性和病人的获得感。三〇二医院自2016年1月启动医院官方手机APP平台建设,提供了预约挂号、停诊通知、自助缴费、检查化验结果查询、医疗咨询等功能,截至目前注册用户111481人,预约挂号量60350人次,日均使用人数6541人。9月底开通了复诊病人预约住院功能,极大地方便了外地患者。

在技术方面,突出特色,锁定需求。三〇二医院提供的特色技术和专业慢病管理主要有:肝移植随访门诊、中西医结合门诊、非酒精性脂肪肝门诊、药物性肝损害门诊、自身免疫性肝病门诊、爱心门诊、丙肝门诊、干扰素相关甲状腺疾病门诊等。依靠“人无我有、人有我精”的特色,才能造福患者,培养人才,实现医院发展。

提升非药物治疗比例 摆脱药品加成依赖

传染病和肝病治疗一般以内科药物治疗为主,但作为传染病专科医院,必须要发展非药物治疗手段和危重病人救治能力,这才是医改分级诊疗的目的,也是集中资源优势提供医疗服务的初衷,传染病医院必须主动作为。

去年,三〇二医院胃肠镜检查治疗总量是19017人次,不仅有效降低了上消化道出血患者的死亡率和手术率,而且改善了病人生存质量,解决了以前只有消化科才能解决的问题。透析治疗是重症肝病患者的有效手段,血液净化中心开展乙肝、丙肝、艾滋、梅毒等分区治疗,在相应传染病重症的治疗中发挥着不可替代的作用。同时,院内也加强肝衰竭诊疗中心建设,专门成立HDU(高度依赖病房),有效衔接普通抢救室和ICU之间,提升了重症病人治疗能力,节约了有限的ICU资源。2015年,急救部与ICU合并组成了重症医学中心,整合了危重患者的收容平台和病房资源,在原有呼吸机、中央监护、血滤机、胃肠镜等设备基础上,增配ECMO,使重症救治能力快速发展。

拓展医院服务范围 满足一站式诊疗需求

医改督促各传染病医院尽快降低药费比,医院必须围绕传染病专科需求挖掘技术手段和技术应用,拓展传染病服务范围,搭建平台,孵育发展。

三〇二医院在肝胆外科的基础上逐渐分支出了移植外科,在普通外科的基础上分支出了门脉高压外科,在青少年肝病的需求牵引下,新建了感染产科和新生儿科,在肝脏肿瘤放疗科的基础上又发展建设了肝外肿瘤放疗科。

传染病患者的需求是在医院得到专业的一站式服务,正是这种需求激励医院不断拓展服务范围,满足患者需求。

抓住传染病相关肿瘤诊治 为患者提供权威服务

肿瘤发病率在不断提升,然而,人类医学已经明确的传染病相关肿瘤不多,传染病医院应该在诊断、治疗、病源研究和疫苗预防等领域开展临床研究和实践,努力为患者提供专业化、综合化服务。

三〇二医院目前开展的肝癌治疗,正在三个层面上推进肿瘤学科群的建设。一是完善肿瘤治疗的手段,如内科药物靶向治疗、细胞生物治疗、微创消融治疗,外科手术治疗、介入科介入消融治疗,放疗科局部放疗,中医科中西医结合治疗;二是落实肿瘤多中心会诊评估机制,在医院层面而不是单个科室层面上形成个体化适宜的诊疗方案;三是实施肿瘤疗效和生存期随访评估,形成数据库,开展必要的临床科研,不断优化院内多中心评估的原则、路径和方案。

以特色技术为驱动 形成学科链的整体跃升

特色技术是医院建设必须高度重视并主动培育的,虽然投入大、风险高,但会为医院发展带来类似蝴蝶效应的推动作用,值得悉心培植。

肝移植是三〇二医院2005年开展的特色技术,曾因肝源问题走入低谷。2015年底,我们抓住机遇,大力开展DCD,2016年肝移植手术突破100例,今年到8月底已完成85例。肝移植的意义已突破了这项技术本身,而且还促进了肝衰竭诊疗水平的快速提升,与内外科联手打造的终末期肝病治疗学科链相伴前行,共同进步。三〇二医院2007年开始酝酿国内首个肝病ICU病房,培育重症肝病诊疗技术,2009年建成启用,不仅提高了重症肝衰竭的救治能力,而且经过多年来的持续发展,肾、胃肠道、中枢神经、心、肺等肝外器官的支持治疗水平和全身营养状态管理能力都大幅提升,不仅为医院传染病重症救治、开展高难度手术保驾护航,而且在援非抗埃、抢险救灾中都发挥了重症医学的巨大作用。

促进科教全面发展 支撑核心业务可持续发展

传染病医院不仅要做科研,而且要做高水平的临床科研。大量的临床问题在日常工作中产生,特色的病人资源集中收治,需求和对象同时具备,这就要求医院积极鼓励、推动和引导临床科研工作,及时总结科研成果,再将科研结论有效的通过教学传承下去,整体提升全体医务人员的科学思维习惯和能力,促进医疗工作健康发展。

另外,对于祖国医学中宝贵的有效经验方、中医治疗手段等也应成立攻关小组,集智研究,总结形成有效的治疗方案或者院内自制制剂,形成医院疗效上的杀手锏。科研、教学和医疗一旦形成良性循环,医院必将实现快速的可持续发展。

快问快答:

Q:您如何看待传染病医院在新时代的责任?

A:人类文明消灭了一部分传染病,同时又无法停止地酝酿着某些更危险的传染病,在当前国家和地方尚未明确给予传染病医院财政支持政策的情况下,传染病医院必须一边在医改中谋定发展,一边随时面对新突发疫情的考验,这既是双重使命,也是双重压力,是新一代“传染人”的责任。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=275869, encodeId=d84b2e58698d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 00:31:50 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275421, encodeId=4dcc2e54219c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jan 04 15:23:33 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286910, encodeId=3763128691029, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Thu Jan 04 03:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275032, encodeId=de392e5032df, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Wed Jan 03 11:44:48 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274758, encodeId=2ae32e475829, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Tue Jan 02 15:34:31 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274739, encodeId=c99a2e473909, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jan 02 13:48:52 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-06 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=275869, encodeId=d84b2e58698d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 00:31:50 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275421, encodeId=4dcc2e54219c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jan 04 15:23:33 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286910, encodeId=3763128691029, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Thu Jan 04 03:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275032, encodeId=de392e5032df, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Wed Jan 03 11:44:48 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274758, encodeId=2ae32e475829, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Tue Jan 02 15:34:31 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274739, encodeId=c99a2e473909, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jan 02 13:48:52 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-04 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=275869, encodeId=d84b2e58698d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 00:31:50 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275421, encodeId=4dcc2e54219c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jan 04 15:23:33 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286910, encodeId=3763128691029, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Thu Jan 04 03:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275032, encodeId=de392e5032df, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Wed Jan 03 11:44:48 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274758, encodeId=2ae32e475829, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Tue Jan 02 15:34:31 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274739, encodeId=c99a2e473909, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jan 02 13:48:52 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-04 tidiq
  4. [GetPortalCommentsPageByObjectIdResponse(id=275869, encodeId=d84b2e58698d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 00:31:50 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275421, encodeId=4dcc2e54219c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jan 04 15:23:33 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286910, encodeId=3763128691029, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Thu Jan 04 03:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275032, encodeId=de392e5032df, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Wed Jan 03 11:44:48 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274758, encodeId=2ae32e475829, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Tue Jan 02 15:34:31 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274739, encodeId=c99a2e473909, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jan 02 13:48:52 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-03 137****9095

    henhao

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=275869, encodeId=d84b2e58698d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 00:31:50 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275421, encodeId=4dcc2e54219c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jan 04 15:23:33 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286910, encodeId=3763128691029, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Thu Jan 04 03:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275032, encodeId=de392e5032df, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Wed Jan 03 11:44:48 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274758, encodeId=2ae32e475829, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Tue Jan 02 15:34:31 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274739, encodeId=c99a2e473909, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jan 02 13:48:52 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-02 1e0e5a1fm42(暂无匿称)

    henhao

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=275869, encodeId=d84b2e58698d, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jan 06 00:31:50 CST 2018, time=2018-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275421, encodeId=4dcc2e54219c, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Thu Jan 04 15:23:33 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286910, encodeId=3763128691029, content=<a href='/topic/show?id=ebac3442063' target=_blank style='color:#2F92EE;'>#医改#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34420, encryptionId=ebac3442063, topicName=医改)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3e9205, createdName=tidiq, createdTime=Thu Jan 04 03:30:00 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275032, encodeId=de392e5032df, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=353a2047758, createdName=137****9095, createdTime=Wed Jan 03 11:44:48 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274758, encodeId=2ae32e475829, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=7dcf1938111, createdName=1e0e5a1fm42(暂无匿称), createdTime=Tue Jan 02 15:34:31 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274739, encodeId=c99a2e473909, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Jan 02 13:48:52 CST 2018, time=2018-01-02, status=1, ipAttribution=)]
    2018-01-02 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

Baidu
map
Baidu
map
Baidu
map